TERN 241220 7.00C (TERN241220C7000) Stock Options, News & Quotes

0.19
+0.04+26.67%

15min DelayClose Dec 13 16:00 ET

0.20High0.15Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Dec 3 06:10

Update

$Terns Pharmaceuticals (TERN.US)$ Terns Pharmaceuticals Announces Positive Early Data From Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
GlobeNewswire· 7 mins ago
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels
Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts
High leve...

frogoracletrading

Oct 30 16:10

$TERN Support / Resistance Levels

Brought it back down into the POC. If 6.47 holds could see it start curling but if shorts get control could see a push down towards 5.00
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$

frogoracletrading

Oct 13 14:49

$TERN Support / Resistance Levels

Back into the 240 day POC. Watch for the 7.33 level to form as a new base.
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$

Jaguar8

Sep 9 15:02

NEWS: $125M public offering

$Terns Pharmaceuticals (TERN.US)$
Terns Announces Proposed Public Offering
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $125 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $18.75 million of shares. Jefferies, TD Cowen, and UBS Investment Bank are acting as bookrunners for the offering.
Terns intends to...

Jaguar8

Sep 9 06:21

NEWS

$Terns Pharmaceuticals (TERN.US)$
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
Terns Pharmaceuticals (Nasdaq: TERN)announced positive Phase 1 clinical trial results for TERN-601, its once-daily oral GLP-1R agonist for obesity treatment. The trial showed:
- Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo-adjusted)
- Well-tolerated with no treatment-related dose ...